Ergoteles’s Neurocrine Biosciences NBIX Stock Holding History

Ergoteles’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,023	Closed	-$839K	–	1591
2022 Q4	$839K	Buy	+7,023	New	+$823K	0.03%	524
2022 Q3	–	Sell	-14,190	Closed	-$1.38M	–	1834
2022 Q2	$1.38M	Buy	+14,190	New	+$1.31M	0.04%	416

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ergoteles's NBIX Position: Q1 2023 in Review

Ergoteles sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 7,023 shares — an estimated $839K sold.

Ergoteles first reported a position in NBIX in Q2 2022 and held it in 2 quarters. The position peaked at $1.38M in Q2 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

Ergoteles reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 7,023 Neurocrine Biosciences shares in Q1 2023, an estimated $839K.
Ergoteles first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 2 quarters.
Ergoteles's Neurocrine Biosciences position peaked at $1.38M in Q2 2022.
486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.